3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
4
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Polycystic Ovary Syndrome
2
Infertility
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Leiomyoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal
1
Breast Neoplasm Female
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Anovulation
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced HR+/HER2- Breast Cancer
1
Interventions
ribociclib
1
palbociclib
1
abemaciclib
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral Breast Neoplasms
×
Letrozole
×
30 days
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled